DNMT inhibitors (DNMTi’s) such as 5-azacytidine or decitabine have been approved for treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and act in part by reactivating genes silenced by abnormal promotor hypermethylation [11]. This evidence concerns the gene DNMT1 and myelodysplastic syndrome.